Live
- Curfew relaxation extended in 5 Manipur districts on Friday
- Tab scam prompts Bengal govt to adopt caution over fund disbursement
- Tata Power inks pact with ADB for green projects worth $4.25 billion
- Globus Spirits Limited introduces India Single Malt under the brand DÅŒAAB India Craft Whisky
- BGT 2024-25: No greater honour to lead India in Test cricket, says Bumrah ahead of series opener
- NMO Bharat calls for apology from Rahul Gandhi over ageist remarks about Joe Biden
- Centre blocks 17,000 WhatsApp accounts of hackers from South-East Asia
- Learn from Mumbai hoarding collapse, Calcutta HC tells Bengal municipal corporation
- Russian Spokesperson Instructed to Stay Silent on ICBM Strike During Press Conference: Viral Video
- Intellipaat Sets New Benchmark with First-of-its-kind Physical Labs for Electric Vehicle Training in Chennai and Pune
Phase-III clinical trial for Covaxin begins at NIMS in Hyderabad
Phase-III clinical trial for Covaxin begins at NIMS in Hyderabad
The Phase-III human clinical trails for Covaxin has begun at Nizam's Institute of Medical Sciences (NIMS) in Hyderabad on Monday.
The Phase-III human clinical trails for Covaxin has begun at Nizam's Institute of Medical Sciences (NIMS) in Hyderabad on Monday. A medical team at NIMS said that the vaccine will be given for 600 volunteers in the phase-III and will be monitored closely.
Phase-I and II trails have said to be successful as no volunteer developed any sign of illness. The Indian Council of Medical Research (ICMR) is planning to bring the vaccine by February. The vaccine is being jointly developed by Bharat Biotech and ICMR.
Bharat Biotech approached Drugs Controller General of India (DCGI) on October 2 for the phase-III trails of Covaxin and the permission was accorded at SEC meeting held in New Delhi on October 19.
The phase-III human trails of Covaxin are being carried out at 19 places including Delhi, Mumbai, Patna, Odisha and Lucknow.
